Lanadelumab and Cardiovascular Risk: Findings From the Phase 3 HELP Study
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.138
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2019
Authors
Publisher
Elsevier BV